Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Shares Outstanding (Weighted Average) (2016 - 2025)

Vistagen Therapeutics' Shares Outstanding (Weighted Average) history spans 12 years, with the latest figure at $42.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 37.8% year-over-year to $42.2 million; the TTM value through Dec 2025 reached $42.2 million, up 37.8%, while the annual FY2025 figure was $30.9 million, 59.53% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $42.2 million at Vistagen Therapeutics, up from $33.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $86.1 million in Q1 2021 and bottomed at $6.3 million in Q2 2021.
  • The 4-year median for Shares Outstanding (Weighted Average) is $30.6 million (2024), against an average of $25.9 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) plummeted 91.68% in 2021 before it skyrocketed 317.11% in 2024.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $6.7 million in 2021, then soared by 131.79% to $15.6 million in 2023, then surged by 96.06% to $30.6 million in 2024, then surged by 37.8% to $42.2 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Shares Outstanding (Weighted Average) are $42.2 million (Q4 2025), $33.9 million (Q3 2025), and $31.9 million (Q2 2025).